A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma by Ji Zhu et al.
Zhu et al. Radiation Oncology 2013, 8:130
http://www.ro-journal.com/content/8/1/130RESEARCH Open AccessA phase II trial of neoadjuvant IMRT-based
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Purpose: Neoadjuvant chemoradiation has become the standard treatment in locally advanced rectal cancer
(LARC) and improves local control. This study explored the feasibility of an intensified chemoradiation treatment
followed by one cycle of capecitabine before surgery for LARC.
Methods and materials: Patients with histologically confirmed, newly diagnosed, locally advanced rectal
adenocarcinoma (cT3-T4 and/or cN+) located within 12 cm of the anal verge were included in this study. Patients
received intensity-modulated radiation therapy (IMRT) to the pelvis (total dose 44 Gy in 20 fractions), as well as
concurrent oxaliplatin (50 mg/m2 d1 weekly) and capecitabine (625 mg/m2 b.i.d. d1–5 weekly). One cycle of
capecitabine (1000 mg/m2 b.i.d. d1–14) was given two weeks after the completion of concomitant chemoradiation,
and radical surgery was scheduled six weeks after chemoradiation.
Results: Between October 2007 and November 2008, a total of 42 patients were enrolled in the study (median age
51 years; 31 male). Of these, 38 underwent surgical resection and 4 refused radical surgery because of almost complete
primary tumor regression and complete symptom relief after neoadjuvant therapy. Fifteen patients underwent
sphincter-sparing lower anterior resection. Six patients had a pathological complete response (pCR). The incidence of
grade 3 hematologic, gastro-intestinal, and skin toxicities were 4.7%, 14.3%, and 26.2%, respectively. Grade 4 toxicity
was not observed. Surgical complications (incisional infection within 2–3 weeks after surgery) were observed in 5
patients. Good responders (defined as TRG 3–4) had a significant difference in DFS (81.6% vs. 16.8%, respectively;
p = 0.000) and OS (83.9% vs. 40.7%, respectively; p = 0.007) compared to those who were evaluated as TRG 1–2.
Conclusions: Our study indicates that neoadjuvant chemoradiation followed by one cycle of capecitabine before
surgery has a good treatment efficacy, with only mild toxicities associated with chemoradiation and acceptable
surgical complications. Treatment response was an early surrogate marker and correlated to oncologic prognosis.
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Neoadjuvant chemoradiation (CRT) followed by total
mesorectal excision is the standard of care for patients
with locally advanced rectal cancer (LARC). One of the
benefits of neoadjuvant CRT is that patients with increased* Correspondence: zhenzhang6@gmail.com
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reproduction in any medium, provided the ortumor downstage, such as pathological complete response
(pCR), may have a better treatment outcome.
In a previous trial, patients with pathological stage T0-2
after preoperative CRT had significantly better long-term
survival compared to those with less tumor downstage,
such as pathological T3-4 tumors [1]. In an Italian retro-
spective study of 566 pCR patients, the 5-year rate of
disease-free survival (DFS), overall survival (OS) and
cancer-specific survival after neoadjuvant therapy increased
to 85%, 90% and 94%, respectively [2]. Compared with
results from other studies in stage II/III rectal cancer
patients, these reports are encouraging and indicate that. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factor in neoadjuvant CRT. Therefore, increasing the pCR
rate is a key goal and neoadjuvant chemoradiotherapy
may be an effective therapy for LARC patients.
In a retrospective analysis of 3,157 patients enrolled in
seven randomized Phase III trials and 45 Phase II trials,
the use of continuous infusion 5-FU, a second drug based
on 5-FU and a higher radiation dose was associated with
higher rates of pCR [3]. However, based on four reported
randomized clinical trials, there was a conflict whether
patients could benefit from additional oxaliplatin in the
neoadjuvant CRT [4-7]. Three previous trials indicated
significantly increased rates of grade 3/4 toxicity, with
no improvement in pCR or sphincter preservation.
However, in the CAO/ARO/AIO-04 trial, which had the
largest sample size of the four trials, it was concluded
that inclusion of oxaliplatin into modified fluorouracil-
based combined modality treatment was feasible and
led to more patients achieving a pathological complete
response compared to standard treatment. Thus, a bal-
ance is needed between tumor response and toxicity in
determining the optimal treatment regimen. Applied
advanced radiation technology with intensified treatment
may maintain this balance.
We designed this study to increase the fractional dose of
radiation therapy to 2.2 Gy using an intensity-modulated
radiotherapy (IMRT) technique. This approach may trans-
late to a higher biologic effective dose (BED) compared
with standard fractionation and has been proven to be
effective in head and neck cancer [8,9]. Due to the un-
certain toxicity in rectal cancer, the total dose used in
this study was 44 Gy in 2.2 Gy/fraction, which is equiva-
lent to 45 Gy in 1.8 Gy/fraction, assuming an α/β of 10 for
tumor control [10]. Additionally, a cycle of capecitabine
was scheduled two weeks after the end of chemoradiation
to increase the treatment intensity without extending the
interval between chemoradiation and surgery. This phase
II study was approved by our institutional review board.
Methods and materials
Eligibility criteria
Between October 2007 and November 2008, a total of
42 patients with histologically confirmed, newly diagnosed,
LARC (cT3-T4 and/or cN+) located within 12 cm of the
anal verge were included in this study. Thirty-one patients
were men and 11 were women, and the median age was
51 years (range, 26–73 years). All patients were ≥ 18 years
of age and had a Karnofsky Performance Status score of
≥ 60, no evidence of distant metastases, adequate bone
marrow function (leukocyte count > 4,000/mL and plate-
let count > 100,000/mL), and adequate renal and hepatic
function (creatinine clearance > 50 mL/min and biliru-
bin ≤ 2 mg/mL). Patients were excluded if they were
older than 75 years of age, had undergone previous pelvicradiotherapy or previous chemotherapy, or had previous
or synchronous tumors other than nonmelanoma skin
cancer. Patients suffering from the following conditions
were also ineligible: ischemic heart disease, inflammatory
bowel disease, malabsorption syndrome, peripheral neur-
opathy, or psychological disorders. Informed consent was
signed and obtained from all patients before treatment.
Pretreatment evaluation
Pretreatment evaluation was performed within two weeks
before initiation of chemoradiation. The evaluation in-
cluded a complete history and physical examination,
including digital rectal examination, complete blood count,
hepatic and renal function tests, tumor marker measure-
ment, colonoscopy and biopsy, computed tomography
(CT) of the thorax and abdomen, magnetic resonance
imaging (MRI) of the pelvis, and, in selected patients,
endorectal ultrasound. All patients were clinically staged
with the AJCC 6th version manual.
Combined chemoradiotherapy
Radiotherapy
Patients were immobilized in the prone position using a
belly board and underwent a non-contrast-enhanced,
planning CT scan with a 5-mm slice from the L3-L4
junction to 2 cm below the perineum. The image data
sets were transferred to the PINNACLE planning system
(Philips Radiation Oncology Systems, Milpitas, CA). The
definitions of volumes were in accordance with the ICRU
Report #83 [11]. The gross tumor volume (GTV) was
defined as all known gross disease determined from CT
and MRI. The clinical target volume (CTV) was defined
as the GTV plus areas considered at significant risk of
harboring microscopic disease, including the mesorectum
(perirectal fascia), presacral region, and internal iliac
lymph region. Based on our institution set-up data, the
planning target volume (PTV) was generated by adding
an 8-mm margin around the CTV in lateral and anterior-
posterior directions, and a 10-mm margin in the superior-
inferior direction. The critical normal organs at risk (OARs)
outlined were the bladder, femoral heads, and small bowel.
The level of outlined small bowel volume was 1 cm above
the PTV.
The PTV was prescribed with a total of 44 Gy in 2.2
Gy/fraction, which was an equivalent dose to a total of
45 Gy in 1.8 Gy/fraction based on the LQ isoeffect equa-
tion [12]. The IMRT plans were generated using the
inverse planning module of PINNACLE for a 6-MV
linear accelerator, with five to seven coplanar fields. The
D2%, D50%, and D98% were set at 41.8 Gy, 44 Gy, and
46.2 Gy, respectively. The dose of the OARs was set as
low as possible and had to at least meet the following
constraints: bladder, ≥ 45 Gy in 15% volume and ≥ 40 Gy
in 40% volume; femoral heads, ≥ 45 Gy in 25% volume
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65 cc volume, ≥ 40 Gy in 100 cc volume, and ≥ 35 Gy
in 180 cc volume.
Patient positioning and isocenter verification were
initially checked using X-ray films for anterior and lat-
eral gantry positions by visually comparing the digitally
reconstructed radiographs.
Concurrent and neoadjuvant chemotherapy
Capecitabine combined with oxaliplatin was administered
concurrently with pelvic radiation. Capecitabine was
given at a dose of 625 mg/m2 twice daily from Monday
to Friday throughout the whole course of IMRT. Oxaliplatin
at a dose of 50 mg/m2 was administered weekly during
the four-week course of radiotherapy. Two weeks after
concurrent chemoradiation, one cycle of capecitabine
(1000 mg/m2) was administered twice daily from day
1–14 (Figure 1).
Surgery and histopathology
Surgery was scheduled 8 weeks after the completion of
CRT. Total mesorectal excision (TME) was mandatory,
whereas the form of surgery (anterior resection or
abdominal-perineal resection) and whether a temporary
colostomy should be performed were decided by the
surgeon. All lymph nodes were examined according to
standard procedures. If the number of lymph nodes was
less than 12, two pathologists were needed to sign to
ensure the reliability of the detection result. The circum-









Figure 1 Preoperative chemoradiotherapy using capecitabine and oxthe method of Quirke et al. [13], and a margin of < 1 mm
was considered CRM-positive. All sections of the sur-
gical specimens were reviewed by two pathologists. The
pathologic stage (ypTN) was recorded according to the
International Union Against Cancer TNM system. Tumor
regression grading (TRG) was evaluated according to
the criteria by Dworak et al. as follows [14]: Grade 0:
no regression; Grade 1: dominant tumor mass with ob-
vious fibrosis and/or vasculopathy; Grade 2: dominantly
fibrotic changes with few tumor cells or groups (easy to
find); Grade 3: very few (difficult to find microscopically)
tumor cells in fibrotic tissue with or without mucous
substance; Grade 4: no tumor cells, only a fibrotic mass
(total regression or response).
Adjuvant chemotherapy
All patients were recommended to receive adjuvant chemo-
therapy regardless of pathological stage. Adjuvant chemo-
therapy consisted of 6–8 cycles of Xelox with oxaliplatin
(130 mg/m2) on day 1 and capecitabine (1000 mg/m2) twice
daily from day 1–14, repeated every 21 days.
Toxicity
Toxicities were evaluated and recorded weekly according
to the CTC 3.0 criteria. If grade 3 toxicities occurred,
the physicians determined causes and decided the response.
In general, the sequence of dose reduction or suspension
moved from oxaliplatin to capecitabine to radiotherapy,






aliplatin in patients with locally advanced rectal cancer.






≤ 50 years 20 47.6%
> 50 years 22 52.4%
Distance from anal verge
≤ 5 cm 27 64.3%









Table 2 Toxicity during the course of chemoradiation
Grade 1 Grade 2 Grade 3
n % n % n %
Diarrhea 15 35.71% 12 28.57% 5 11.90%
Hematologic 8 19.05% 8 19.05% 1 2.38%
Fatigue 8 19.05% 5 11.90% 3 7.14%
Radiation dermatitis 5 11.90% 18 42.86% 9 21.43%
Neurosensory 1 2.38% 1 2.38% 1 2.38%
Hand-foot syndrome 2 4.76% 0 0.00% 0 0.00%
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The primary endpoint for this trial was pCR rate. This
study was a phase II trial of 42 patients to evaluate the
treatment feasibility and efficacy of this dosing regimen.
Based on the published literature, the pCR rate is approxi-
mately 10–15% for patients treated with neoadjuvant CRT.
We determined that an experimental arm with a pCR rate
of at least 15% would merit further study. In this study,
with 42 analyzable patients, we had 80% power to reject
the null hypothesis that the true number of pCR was ≤ 3,
with a type I error level of 5%. Secondary endpoints
included safety, sphincter preservation rate, TRG, local
recurrence, DFS and OS. Sphincter preservation was
defined as any procedure in which the rectal tumor
was removed while leaving behind the anal sphincter.
All characteristics were described by the frequency for
classified variables, by mean and standard deviations for
normal distributional continuous data, and by the median
for non-normal distributional continuous data.
Survival time was calculated from the beginning of CRT
to the date of event or the last follow-up, and survival
curves were estimated using the Kaplan-Meier method.
Results
Clinical characteristics
All 42 patients included in this study were diagnosed
with locally advanced rectal cancer, including 28 patients
with cT3 and 14 with cT4 primary tumors. Lymph node
involvements were detected in 37 patients. Twenty-seven
patients (64.3%) had a tumor located ≤ 5 cm from the anal
verge (Table 1).
Acute oxicities and treatment compliance
All patients completed the prescribed radiation treatment
to a total dose of 44 Gy in 20 fractions. The median total
radiation duration was 26 days (range, 26–31 days). All
patients completed concurrent oral capecitabine, and 32
patients received four cycles of weekly oxaliplatin during
the course of radiotherapy. In addition, all patients re-
ceived a scheduled single cycle of capacitabine two weeks
after the completion of chemoradiotherapy without dose
adjustment.
Most of the adverse events of this regimen were mild
(grade 1 or 2). Only two patients were evaluated with
grade 3 hematological toxicities, while grade 3 diarrhea
and anal skin toxicities occurred in 6 and 11 patients,
respectively. No grade 4 or 5 toxicities were observed
(Table 2).
Surgical procedures and complications
Surgical resection was performed in 38 patients, and the
median interval between chemoradiotherapy and surgery
was 43 days (range, 38–53). The remaining four patients
refused a radical surgery due to almost complete primarytumor regression and complete symptom relief after
neoadjuvant therapy. Thirty-five patients underwent R0
surgical resection, while 15 patients underwent sphincter-
sparing lower anterior resection. Incisional infection oc-
curred in 5 patients 2–3 weeks after surgery. No other
surgical complications were observed, including anasto-
motic fistula and abscesses.Pathological response and TRG score
TRG information was available in pathologic examin-
ation for all 38 patients receiving surgery. The TRG
stage was Grade 4 (pCR) in 6 patients, Grade 3 in 17 pa-
tients, Grade 2 in 11 patients, and Grade 1 in 4 patients.
Lymphatic/vascular invasion and neural invasion were
confirmed in 4 and 8 cases, respectively. All pathological
features are listed in Table 3.
Table 3 Surgical procedure and pathological findings
n %
Surgery
Lower anterior resection 20 52.6%
Abdominal perineal resection 15 39.5%
Hartmann 3 7.9%

























Figure 2 Kaplan-Meier analysis of local recurrence, overall
survival (OS) and disease-free survival (DFS).
Table 4 Late urinary, rectal, and sexual function-related




Urinary function Rectal function Sexual function
Num % Num % Num %
0 22 75.86 26 89.66 24 82.76
1 5 17.24 2 6.90 5 17.24
2 2 6.90 1 3.45 0 0.00
3 0 0.00 0 0.00 0 0.00
4 0 0.00 0 0.00 0 0.00
LENT/SOMA Late Effects on Normal Tissue / Subjective, Objective, Management
and Analytic.
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With a median follow-up of 26 months (range, 5–55
months), 3 patients were diagnosed with local recurrence
and 10 patients were confirmed with distant metastases
(5 in the liver, four in the lung, and 1 in bone). Nine
patients died of rectal cancer. For the four patients that
did not receive surgery, one patient died of another
disease at 32 months after CRT, and the other three
patients did not present any evidence of tumor failure.
The 3-year local recurrence, DFS and OS rates were 12.8%,
57.4% and 66.0%, respectively (Figure 2). Late Effects on
Normal Tissue / Subjective, Objective, Management and
Analytic (LENT/SOMA) scales were used to evaluate
late toxicities after radiation. The questionnaires were
returned and available for analysis for 29/42 patients.
LENT/SOMA median scores were less than 1 and no
grade 3/4 late toxicities were indicated (Table 4).Subgroup analysis
The 38 patients receiving surgery were divided into two
subgroups: good responders (defined as TRG 3–4) or
poor responders (defined as TRG 1–2). A significant
difference in DFS (81.6% vs. 16.8%, p=0.000) and OS
(83.9% vs. 40.7%, p=0.007) was observed between the
two groups, as shown in Figures 3 and 4, respectively.
Discussion
Neoadjuvant chemoradiation followed by surgery has
been the standard care for LARC. Treatment of patients
with pathologic CR after neoadjuvant chemoradiation
has been shown to correlate to better local control and
improved survival [1,2]. The aim of our study was
to investigate the feasibility of an increased dose of
chemoradiation in rectal cancer and to achieve high
pCR. However, an increased dose could be accompanied
by toxicities such as diarrhea. In our study, a modified
strategy of neoadjuvant CRT followed by a cycle of
capecitabine resulted in a pCR rate of 15.8%, which was
Figure 3 Kaplan-Meier analysis of disease-free survival (DFS) in
patients based on their response to treatment.
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current with fluorouracil and oxaliplatin (16% - 20.9%).
Regarding toxicities, our study showed that the inci-
dence of grade 3 diarrhea, hematologic toxicity, and
radiation dermatitis was 11.90%, 2.38% and 21.43%, re-
spectively. Compared with other published stage III clin-
ical trials [4-7], the incidence of diarrhea and hematologic
toxicity in our study were slight lower. However, there was
a significant increase in the incidence of radiation derma-
titis in our study, which might be attributed to a lower
irradiation field due to a distal rectal tumor location in
most cases.
IMRT is an advanced technique of high-precision radio-
therapy that utilizes computer-controlled linear acceleratorsFigure 4 Kaplan-Meier analysis of overall survival (OS) in
patients based on their response to treatment.to deliver precise radiation doses to tumor areas. It allows
higher radiation doses to be focused on regions within the
tumor while minimizing the dose to surrounding normal
critical structures. The data of dosimetric studies for IMRT
in rectal cancer are encouraging. Henry Mok et al. com-
pared IMRT with 3DCRT in 10 patients, and IMRT showed
similar target coverage with reduced dose to the small
bowel, bladder, pelvic bone and femoral heads [15]. Wolff
et al. concluded that IMRT had a better conformity index
and reduced the dose to the OAR compared to 3DCRT
[16]. Guerrero Urbano and colleagues also reported that
the volume of 45 Gy to the small bowel decreased more
than 64% via IMRT [17]. By decreasing the dose delivered
to normal structures, IMRT may provide a potential for
increasing treatment dose to improve tumor response;
however, the results of clinical outcomes for IMRT in
rectal cancer are conflicting. To pursue the possibility
of dose escalation, our strategy was to increase the radi-
ation dose in two phases: the first phase increased the
fractional dose to 2.2 Gy and total dose to 44 Gy, and
the second phase increased the total dose based on the
results from the first phase.
In the setting of neoadjuvant chemoradiation, the
optimal sequencing of preoperative CRT and CT before
resection of rectal cancer has been studied in several trials.
In the study by Fernandez-Martos et al., four cycles of
Capox were administered before preoperative CRT. They
obtained a similar tumor response and a significantly
decreased toxicity compared with conventional neoadjuvant
CRT followed by surgery and adjuvant chemotherapy [18].
However, this treatment model prolonged the interval
between initial therapy and surgery, which may increase
patients’ psychological and financial burdens, especially
for those with poor response to chemotherapy. There-
fore, in this study, one cycle of capecitabine was pre-
scribed in the interval between CRT and surgery, which
increased the dose of preoperative therapy without
delaying the schedule of surgery. Our results showed
that the additional cycle of capecitabine did not increase
surgical complications. Taken together, this indicates that
capecitabine is effective for neoadjuvant chemoradiotherapy
in patients with locally advanced rectal cancer.
Finally, our follow-up data showed that the treatment
response to neoadjuvant CRT was an early indicator
and correlated to long-term prognosis. Tumor response
(good vs. poor) was associated with 3-year DFS (81.6% vs.
16.8%, p=0.000) and 3-year OS (83.9% vs. 40.7%, p=0.007).
A similar conclusion was also reported by other studies.
In a study at the MD Anderson Cancer Center, 725 pa-
tients were classified by tumor response to neoadjuvant
chemoradiation (complete, intermediate and poor), and
tumor response was associated with the 5-year recurrence-
free survival, distant-metastasis rate and local recurrence
[19]. The CAO/ARO/AIO-94 trial demonstrated that the
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TRG 4 patients, 75% for grouped TRG 2+3 patients, and
63% for grouped TRG 0+1 patients (P = 0.006) [20]. In a
study in Italy, 566 patients with pCR had an excellent
long-term prognosis [2]. These data provide guidance
with response-stratified oncologic benchmarks for dif-
ferent novel treatment strategies.
Based on our results, the total dose of 44 Gy in
2.2 Gy/fraction was effective and tolerable, with a pCR
rate of 15.8% and mild acute toxicities. A prospective
trial using a concomitant boost of 55 Gy over 25 frac-
tions to the gross tumor is currently ongoing. In conclu-
sion, results from our study indicate that neoadjuvant
chemoradiation followed by one cycle of capecitabine
before surgery has a good treatment efficacy, mild toxic-
ities associated with chemoradiation, and acceptable
surgical complications. Treatment response was an early
surrogate marker and correlated to oncologic prognosis.
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